REDUCTIONS IN EXACERBATIONS IN PATIENTS WITH ALLERGIC (IGE-MEDIATED) ASTHMA RECEIVING OMALIZUMAB IN A REAL-WORLD SETTING

被引：0
|
作者：
Kuo, H. P. [1 ]
Canvin, J.
Maykut, R. [2 ]
Bruce, J. [2 ]
Chen, C. W. [3 ]
Braunstahl, G. J. [4 ]
机构：
[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Taipei, Taiwan
[2] Novartis Pharma AG, Zurich, Switzerland
[3] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[4] St Franciscus Gasthuis, Dept Pulm Med, Gasthuis, Netherlands
来源：
RESPIROLOGY | 2012年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] Safety of Omalizumab in Children with Inadequately Controlled Moderate-Severe Allergic (IgE-Mediated) Asthma.
    Milgrom, H.
    Fink, J.
    Fowler-Taylor, A.
    Vidaurre, C. Fernandez
    Blogg, M.
    Fox, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [42] Omalizumab - Response In Patients With Severe Allergic Asthma In A Real Life Setting
    Zierau, L.
    Walsted, E. S.
    Backer, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [43] Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab
    Ke, Xuehua
    Kavati, Abhishek
    Wertz, Debra
    Huang, Qing
    Wang, Liya
    Willey, Vincent J.
    Stephenson, Judith J.
    Ortiz, Benjamin
    Panettieri, Reynold A., Jr.
    Corren, Jonathan
    CLINICAL THERAPEUTICS, 2018, 40 (07) : 1140 - 1158
  • [44] SAFETY AND TOLERABILITY OF OMALIZUMAB IN CHILDREN WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ALLERGIC (IGE-MEDIATED) ASTHMA
    Milgrom, H.
    Fink, J.
    Fowler-Taylor, A.
    Vidaurre, C. Fernandez
    Blogg, M.
    THORAX, 2009, 64 : A18 - A19
  • [45] Safety and Tolerability of Omalizumab in Children with Allergic (IgE-Mediated) Asthma: A Systematic Review and Meta-Analysis
    Lang, Dandan
    Liu, Zhengmin
    Li, Dejun
    DISCOVERY MEDICINE, 2023, 35 (176) : 233 - 241
  • [46] Real-world patient-level costeffectiveness analysis of omalizumab in patients with severe allergic asthma
    Oguzulgen, Ipek Kivilcim
    Tugay, Deniz
    Top, Mehmet
    Aydin, Omur
    Bavbek, Sevim
    Damadoglu, Ebru
    Erkekol, Ferda Oner
    Kalkan, Ilkay Koca
    Kalyoncu, A. Fuat
    Karakaya, Gul
    Turktas, Haluk
    Abraham, Ivo
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [47] VARIABILITY OF TOTAL IGE CORRELATES WITH THE ANNUAL SEVERE ASTHMA EXACERBATIONS: A PROSPECTIVE COHORT STUDY IN REAL-WORLD SETTING
    Yuan, Yulai
    Zhang, Xin
    Wang, Gang
    RESPIROLOGY, 2019, 24 : 274 - 274
  • [48] Assessment of asthma exacerbations in a real-world setting over 4 years
    O'Connor, R
    Tashkin, D
    Peters, S
    Long, A
    Bleecker, E
    Parasuraman, B
    Boggs, R
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S275 - S275
  • [49] Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
    Barnes, Neil
    Menzies-Gow, Andrew
    Mansur, Adel H.
    Spencer, David
    Percival, Fran
    Radwan, Amr
    Niven, Rob
    JOURNAL OF ASTHMA, 2013, 50 (05) : 529 - 536
  • [50] Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
    Britton, Mark
    Howes, Timothy
    Saralaya, Dinesh
    Hepburn, Deborah
    Nordstrom, Monica
    Welham, Kate
    Regan, Karen
    Kasujee, Ismail
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345